Please assess the completion status of the following clinical trial:

Trial Title: Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 0 to 3 day old infants~* Mother seronegative for Human Immunodeficiency Virus (HIV)~* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg~* Apgar score \>7 at 5 or 10 minutes of life~* Informed consent form signed by a parent or other legal guardian and by an independent witness if the parent or other legal guardian is illiterate~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Current or planned participation in another clinical trial during the entire duration of the present trial~* Suspected congenital or acquired immunodeficiency~* Suspected maternal acute seroconversion syndrome to HIV after 24 weeks gestation based on clinical history~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received since birth~* Any planned vaccination (except Bacille Calmette Guérin and trial vaccinations) from birth to 18 weeks of age~* Oral Poliovirus Vaccine (OPV) administration at birth~* Known maternal history of HIV, Hepatitis B (HB) (HbsAg carrier) or Hepatitis C seropositivity~* Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination~* History of seizures~* Febrile or acute illness on the day of inclusion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP-IPV-Hep B-PRP-T (Type: EXPERIMENTAL): None
- Group 2: CombAct-HIB™ + OPV (Type: EXPERIMENTAL): None
- Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).